AbCellera Biologics
ABCL
116 hedge funds and large institutions have $1.98B invested in AbCellera Biologics in 2021 Q3 according to their latest regulatory filings, with 28 funds opening new positions, 48 increasing their positions, 25 reducing their positions, and 26 closing their positions.
120% more call options, than puts
Call options by funds: $67M | Put options by funds: $30.4M
92% more repeat investments, than reductions
Existing positions increased: 48 | Existing positions reduced: 25
33% more funds holding in top 10
Funds holding in top 10: 6 → 8 (+2)
1.99% more ownership
Funds ownership: 33.42% → 35.41% (+2%)
2% more funds holding
Funds holding: 114 → 116 (+2)
8% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 26
0% less capital invested
Capital invested by funds: $1.99B → $1.98B (-$8.58M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital World Investors
Los Angeles,
California
|
+$113M |
| 2 |
Allianz Asset Management
Munich,
Germany
|
+$34.1M |
| 3 |
Swedbank
Stockholm,
Sweden
|
+$16.9M |
| 4 |
Millennium Management
New York
|
+$13.8M |
| 5 |
DFO
Duquesne Family Office
New York
|
+$11.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$36.1M |
| 2 |
AWG
Alpha Wave Global
New York
|
-$29.4M |
| 3 |
LCM
Laurion Capital Management
New York
|
-$9.9M |
| 4 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
-$9.29M |
| 5 |
Blackstone Inc
New York
|
-$7.7M |
ABCL Hedge Fund Activity: Q3 2021 in Review
116 of the 5,728 institutional investors tracked by Wall St. Rank reported a position in AbCellera Biologics (ABCL) for Q3 2021, worth a combined $1.98B — down 0.43% from $1.99B a quarter earlier.
Buyers outnumbered sellers: 28 funds opened new ABCL positions and 26 closed out — a net gain of 2 holders — while 48 added to existing stakes and 25 trimmed.
The largest buyer was Capital World Investors, adding an estimated $113M. The largest seller was OrbiMed, cutting an estimated $36.1M.
- 116 institutional investors held AbCellera Biologics (ABCL) as of Q3 2021, up from 114 in Q2 2021.
- Funds reported $1.98B of AbCellera Biologics stock for Q3 2021, down 0.43% quarter-over-quarter.
- 28 funds opened new AbCellera Biologics positions in Q3 2021 and 26 closed out, a net change of +2 holders.
- The largest AbCellera Biologics buyer in Q3 2021 was Capital World Investors, an estimated $113M added.
- The largest AbCellera Biologics seller in Q3 2021 was OrbiMed, an estimated $36.1M sold.
Based on aggregated 13F filings for Q3 2021.